By Scientia Professor Gregory John Dore

Journal articles

Wedemeyer H; Dore GJ; Ward JW, 2015, 'Estimates on HCV disease burden worldwide - Filling the gaps', Journal of Viral Hepatitis, 22, pp. 1 - 5, http://dx.doi.org/10.1111/jvh.12371

Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003

Eslam M; Hashem AM; Leung R; Romero-Gomez M; Berg T; Dore GJ; Chan HLK; Irving WL; Sheridan D; Abate ML; Adams LA; Mangia A; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Powell E; Nattermann J; Riordan S; McLeod D; Armstrong NJ; Douglas MW; Liddle C; Booth DR; George J; Ahlenstiel G; Ampuero J; Bassendine M; Wong VWS; Rosso C; White R; Mezzabotta L; Suppiah V; Michalk M; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2015, 'Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease', Nature Communications, 6, pp. 6422, http://dx.doi.org/10.1038/ncomms7422

Applegate TL; Gaudieri S; Plauzolles A; Chopra A; Grebely J; Lucas M; Hellard M; Luciani F; Dore GJ; Matthews GV, 2015, 'Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C', Antiviral Therapy, 20, pp. 199 - 208, http://dx.doi.org/10.3851/IMP2821

Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F; Dolan K; Haber P; Rawlinson W; Treloar C; Dore G; Maher L, 2015, 'Transmitted/founder viruses rapidly escape from CD8⁺ T cell responses in acute hepatitis C virus infection', Journal of Virology, 89, pp. 5478 - 5490, http://dx.doi.org/10.1128/JVI.03717-14

Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ; Han A, 2015, 'Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment', Journal of Hepatology, 62, pp. 269 - 277, http://dx.doi.org/10.1016/j.jhep.2014.09.001

Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, 26, pp. 893 - 898, http://dx.doi.org/10.1016/j.drugpo.2015.07.007

Sievert W; Razavi H; Thompson A; Zekry A; Dore GJ; Roberts SK, 2015, 'HCV‐infected patients need access now to new direct‐acting antiviral agents to avert liver‐related deaths', The Medical Journal of Australia, 202, pp. 479 - 479, http://dx.doi.org/10.5694/mja15.00165

Maher L; White B; Dore G; Lloyd A; Rawlinson W, 2015, 'Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study', Drug and Alcohol Dependence, 146, pp. e191 - e191, http://dx.doi.org/10.1016/j.drugalcdep.2014.09.435

Bretaña N; Boelen L; Bull R; Teutsch S; White P; Lloyd A; Luciani F; Bretana N; Dolan K; Rawlinson W; Dore G; Maher L, 2015, 'Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012.', Emerging Infectious Diseases, 21, pp. 765 - 774, http://dx.doi.org/10.3201/eid2105.141832

Dore GJ; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw DR; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'Tu1015 MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1', Gastroenterology, 148, http://dx.doi.org/10.1016/s0016-5085(15)33704-5

Jacobson IM; Dore GJ; Wyles D; Lawitz E; Talal A; Ball G; Dumas EO; Feld JJ, 2015, 'Tu1024 Plasma Interferon-γ-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis', Gastroenterology, 148, http://dx.doi.org/10.1016/s0016-5085(15)33713-6

Grebely J; Dore GJ; Kim AY; Lloyd A; Shoukry NH; Prins M; Page K, 2014, 'Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn', Hepatology, 60, pp. 2127 - 2128, http://dx.doi.org/10.1002/hep.27163

Razavi H; Bruggmann P; Wedemeyer H; Dore G, 2014, 'Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: A comment on the results presented in JVH Special Issue', Journal of Viral Hepatitis, 21, pp. e169 - e170, http://dx.doi.org/10.1111/jvh.12339

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC³ Study', Journal of Clinical Virology, 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Jacka B; Applegate T; Krajden M; Olmstead A; Harrigan PR; Marshall BDL; Debeck K; Milloy MJ; Lamoury F; Pybus OG; Lima VD; Magiorkinis G; Montoya V; Montaner J; Joy J; Woods C; Dobrer S; Dore GJ; Poon AFY; Grebely J, 2014, 'Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada', Hepatology, 60, pp. 1571 - 1580, http://dx.doi.org/10.1002/hep.27310

Shiffman ML; Cheinquer H; Berg CP; Berg T; de Figueiredo-Mendes C; Dore GJ; Ferraz ML; Mendes-Corrêa MC; Lima MP; Parise ER; Rios AMP; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F; Bakalos G; Zeuzem S, 2014, 'Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial', Hepatology International, 8, pp. 517 - 526, http://dx.doi.org/10.1007/s12072-014-9555-3

Luciani F; Bretaña NAR; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR; Bretana N, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), 109, pp. 1695 - 1706, http://dx.doi.org/10.1111/add.12643

Luciani F; Bretaña NAR; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR; Bretana N, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), 109, pp. 1695 - 1706, http://dx.doi.org/10.1111/add.12643

Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ; Dolan K, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010

Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Regression of advanced fibrosis following virological response to anti-HCV therapy', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 85

Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Safety and efficacy of telaprevir and boceprevir in the "real world": an Australian experience', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 86

Harrod ME; Couzos S; Delaney-Thiele D; Dore GJ; Hammond B; Saunders M; Belfrage M; Williams S; Kaldor JM; Ward J, 2014, 'Markers of hepatitis B infection and immunity in patients attending Aboriginal community controlled health services', Medical Journal of Australia, 201, pp. 339 - 342, http://dx.doi.org/10.5694/mja14.00121

White B; Dore GJ; Lloyd AR; Rawlinson WD; Maher L, 2014, 'Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study', Medical Journal of Australia, 201, pp. 326 - 329, http://dx.doi.org/10.5694/mja13.00153

Crane M; Avihingsanon A; Rajasuriar R; Velayudham P; Iser D; Solomon A; Sebolao B; Tran A; Spelman T; Matthews G; Cameron P; Tangkijvanich P; Dore GJ; Ruxrungtham K; Lewin SR, 2014, 'Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy', Journal of Infectious Diseases, 210, pp. 745 - 751, http://dx.doi.org/10.1093/infdis/jiu119

Boelen L; Teutsch S; Wilson DP; Dolan K; Dore GJ; Lloyd AR; Luciani F; Maher L, 2014, 'Per-event probability of hepatitis C infection during sharing of injecting equipment', PLoS ONE, 9, pp. e100749, http://dx.doi.org/10.1371/journal.pone.0100749

Grebely J; Lima VD; Marshall BDL; Milloy MJ; DeBeck K; Montaner J; Simo A; Krajden M; Dore GJ; Kerr T; Wood E, 2014, 'Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012', PLoS ONE, 9, pp. e97726, http://dx.doi.org/10.1371/journal.pone.0097726

Dore GJ; Ward J; Thursz M, 2014, 'Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)', Journal of viral hepatitis, 21, pp. 1 - 4, http://dx.doi.org/10.1111/jvh.12253

Bruggmann P; Berg T; Øvrehus ALH; Moreno C; Brandão Mello CE; Roudot-Thoraval F; Marinho RT; Sherman M; Ryder SD; Sperl J; Akarca U; Balık I; Bihl F; Bilodeau M; Blasco AJ; Buti M; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Ergör G; Esmat G; Estes C; Falconer K; Félix J; Ferraz MLG; Ferreira PR; Frankova S; García-Samaniego J; Gerstoft J; Giria JA; Gonçales FL; Gower E; Gschwantler M; Guimarães Pessôa M; Hézode C; Hofer H; Husa P; Idilman R; Kåberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Lázaro P; Marotta P; Mauss S; Mendes Correa MC; Müllhaupt B; Myers RP; Negro F; Nemecek V; Örmeci N; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Rosenberg WM; Sarmento-Castro R; Sarrazin C; Semela D; Shiha GE; Sievert W; Stärkel P; Stauber RE; Thompson AJ; Urbanek P; van Thiel I; Van Vlierberghe H; Vandijck D; Vogel W; Waked I; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Van Damme P; Aleman S; Hindman SJ, 2014, 'Historical epidemiology of hepatitis C virus (HCV) in selected countries', Journal of viral hepatitis, 21, pp. 5 - 33, http://dx.doi.org/10.1111/jvh.12247

Wedemeyer H; Duberg AS; Buti M; Rosenberg WM; Frankova S; Esmat G; Örmeci N; Van Vlierberghe H; Gschwantler M; Akarca U; Aleman S; Balık I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brandão Mello CE; Bruggmann P; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; El-Sayed MH; Ergör G; Estes C; Falconer K; Félix J; Ferraz MLG; Ferreira PR; García-Samaniego J; Gerstoft J; Giria JA; Gonçales FL; Guimarães Pessôa M; Hézode C; Hindman SJ; Hofer H; Husa P; Idilman R; Kåberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Lázaro P; Marinho RT; Marotta P; Mauss S; Mendes Correa MC; Moreno C; Müllhaupt B; Myers RP; Nemecek V; Øvrehus ALH; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Sarrazin C; Semela D; Sherman M; Shiha GE; Sperl J; Stärkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Vandijck D; Vogel W; Waked I; Weis N; Wiegand J; Yosry A; Zekry A; Negro F; Sievert W; Gower E, 2014, 'Strategies to manage hepatitis C virus (HCV) disease burden', Journal of viral hepatitis, 21, pp. 60 - 89, http://dx.doi.org/10.1111/jvh.12249

Razavi H; Waked I; Sarrazin C; Myers RP; Idilman R; Calinas F; Vogel W; Mendes Correa MC; Hézode C; Lázaro P; Akarca U; Aleman S; Balık I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brandão Mello CE; Bruggmann P; Buti M; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Ergör G; Esmat G; Falconer K; Félix J; Ferraz MLG; Ferreira PR; Frankova S; García-Samaniego J; Gerstoft J; Giria JA; Gonçales FL; Gower E; Gschwantler M; Guimarães Pessôa M; Hindman SJ; Hofer H; Husa P; Kåberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Marinho RT; Marotta P; Mauss S; Moreno C; Murphy K; Negro F; Nemecek V; Örmeci N; Øvrehus ALH; Parkes J; Pasini K; Peltekian KM; Ramji A; Reis N; Roberts SK; Rosenberg WM; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Semela D; Sherman M; Shiha GE; Sievert W; Sperl J; Stärkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Van Vlierberghe H; Vandijck D; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Cornberg M; Müllhaupt B; Estes C, 2014, 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm', Journal of viral hepatitis, 21, pp. 34 - 59, http://dx.doi.org/10.1111/jvh.12248

Bradshaw D; Lamoury F; Catlett B; Mcallister J; Applegate T; Dore G; Matthews G; Danta M, 2014, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-infected men with acute HCV', HIV MEDICINE, 15, pp. 8 - 8

Bradshaw D; Applegate T; Dore G; Hellard M; Sasadeusz J; Matthews G; Danta M, 2014, 'The majority of acute HCV infection in HIV-positive men who have sex with men (HIV plus MSM) is transmitted permucosally in the context of HIV serosorting in Australia', HIV MEDICINE, 15, pp. 137 - 137

Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L, 2014, 'Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011', Journal of Viral Hepatitis, 21, pp. 198 - 207, http://dx.doi.org/10.1111/jvh.12129

Martin NK; Devine A; Eaton JW; Miners A; Hallett TB; Foster GR; Dore GJ; Easterbrook PJ; Legood R; Vickerman P, 2014, 'Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa', AIDS, 28, pp. s35 - s46, http://dx.doi.org/10.1097/qad.0000000000000084

White B; Madden A; Prins M; Hellard M; Wand H; Dore GJ; Page K; Maher L, 2014, 'Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study', Vaccine, 32, pp. 5460 - 5467, http://dx.doi.org/10.1016/j.vaccine.2014.07.091

Treloar C; Rance J; Dore GJ; Grebely J, 2014, 'Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study', Journal of Viral Hepatitis, 21, pp. 560 - 567, http://dx.doi.org/10.1111/jvh.12183

Peters L; Neuhaus J; Duprez D; Neaton JD; Tracy R; Klein MB; Mocroft A; Rockstroh J; Dore G; Lundgren JD; Emery S, 2014, 'Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study', Journal of Clinical Virology, 60, pp. 295 - 300, http://dx.doi.org/10.1016/j.jcv.2014.03.017

Grebely J; Dore GJ, 2014, 'Can hepatitis C virus infection be eradicated in people who inject drugs?', Antiviral Research, 104, pp. 62 - 72, http://dx.doi.org/10.1016/j.antiviral.2014.01.002

Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J, 2014, 'Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents', Liver International, 34, pp. 1198 - 1206, http://dx.doi.org/10.1111/liv.12370

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', European Journal of Gastroenterology and Hepatology, 26, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', Journal of Nursing Administration, 44, pp. 1003 - 1009, http://dx.doi.org/10.1097/meg.0000000000000150

Grebely J; Grady B; Hajarizadeh B; Page K; Dore GJ, 2014, 'Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?', Hepatology, 59, pp. 1650 - 1651, http://dx.doi.org/10.1002/hep.26675

Roberts SK; Mitchell J; Leung R; Booth D; Bollipo S; Ostapowicz G; Sloss A; Mccaughan GW; Dore GJ; Thompson A; Crawford DH; Sievert W; Weltman M; Cheng W; George J; Angus P; Chu G; Cornwall M; Douglas M; Hallinan R; Haque M; Hawkin G; Jackson H; Johnson R; Kronborg I; Lee A; Leggett B; Mire ML; Levy M; Lubel J; MacQuillan G; Masson J; McDonald J; McGarity B; Mollison L; Nicoll A; Ombiga J; Riordan S; Strasser S; Thompson A; Watson J; Wenman J; Wigg A; Zekry A, 2014, 'Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 179 - 184, http://dx.doi.org/10.1111/jgh.12424

Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ, 2014, 'Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 1 - 9, http://dx.doi.org/10.1111/jgh.12677

Kitson MT; George J; Dore GJ; Leung R; Button P; Mccaughan GW; Crawford DHG; Sievert W; Weltman MD; Cheng WSC; Roberts SK, 2014, 'Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 1458 - 1462, http://dx.doi.org/10.1111/jgh.12544

Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; Mccaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ, 2014, 'ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response', Hepatology, 59, pp. 2152 - 2160, http://dx.doi.org/10.1002/hep.27022

Alavi M; Law MG; Grebely J; Thein HH; Walter S; Amin J; Dore GJ; Han A, 2014, 'Lower life expectancy among people with an HCV notification: A population-based linkage study', Journal of Viral Hepatitis, 21, pp. e10 - e18, http://dx.doi.org/10.1111/jvh.12245

Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M, 2014, 'Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial', The Lancet, 384, pp. 403 - 413, http://dx.doi.org/10.1016/S0140-6736(14)60494-3

Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; Mcgovern BH; Schinkel J; George J; Shoukry NH; Lauer GM; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M, 2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, 59, pp. 109 - 120, http://dx.doi.org/10.1002/hep.26639

Back to profile page